Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15206348 | 0.87 | RAB9A (0.59) | L3MBTL1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL27919282 | 0.80 | CD38 (0.48) | SMN1; SMN2GAANPC1RAB9ATAS1R3 | |
| SCHEMBL8174016 | 0.80 | NPC1 (0.46) | L3MBTL1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL30339452 | 0.80 | PLK1 (0.53) | GAANPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL4155499 | 0.80 | PLK1 (0.53) | GAANPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL6671895 | 0.80 | NPC1 (0.51) | SMN1; SMN2GAANPC1RAB9ATAS1R3 | |
| SCHEMBL13423147 | 0.80 | L3MBTL1 (0.77) | L3MBTL1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL9887785 | 0.79 | TAS1R3 (0.45) | L3MBTL1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL6444002 | 0.78 | NPC1 (0.50) | GAANPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL668153 | 0.78 | P2RX7 (0.53) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2016-02-11 | — | — | US | disclosed |
| US-9255273-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-02-09 | — | — | US | disclosed |
| EP-2460786-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9169210-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150240244-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2015-08-27 | — | — | US | disclosed |
| US-9102648-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-8524948-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130040389-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | Intrexon Coporation (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2463269-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120046322-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-02-23 | — | — | US | disclosed |
| US-7563928-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7456315-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046322-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | L3MBTL1 1671/4885RECQL 3165/4885SMN1; SMN2 4577/4885 |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | L3MBTL1 1671/4885RECQL 3165/4885SMN1; SMN2 4577/4885 |
| US-20130040389-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | L3MBTL1 1671/4885RECQL 3165/4885SMN1; SMN2 4577/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | L3MBTL1 1671/4885RECQL 3165/4885SMN1; SMN2 4577/4885 |
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | L3MBTL1 1671/4885RECQL 3165/4885SMN1; SMN2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.